InspireMD Secures Partner for Intended Registration and Distribution of CGuard EPS in Mainland China
03 févr. 2021 08h32 HE
|
InspireMD
TEL AVIV, Israel, Feb. 03, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid...
InspireMD’s CGuard™ Featured in Multiple Presentations, Including a Live Case Demonstration During the Leipzig Interventional Congress January 25-29, 2021
26 janv. 2021 06h30 HE
|
InspireMD
TEL AVIV, Israel, Jan. 26, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid...
InspireMD Announces Third Quarter 2020 Financial Results
09 nov. 2020 06h30 HE
|
InspireMD
Third quarter 2020 revenue returns to pre-COVID-19 levels Management to host investor conference call today, November 9, 2020 at 8:30 a.m. ET TEL AVIV,...
UPDATE - InspireMD, Inc. Appoints Andrea Tommasoli Senior Vice President of Global Sales and Marketing and Reports Inducement Grants Under NYSE American Company Guide §711(a)
03 nov. 2020 07h53 HE
|
InspireMD
TEL AVIV, Israel, Nov. 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) (“Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke...
InspireMD, Inc. Appoints Andrea Tommasoli Senior Vice President of Global Sales and Marketing and Reports Inducement Grants Under NYSE American Company Guide §711(a)
03 nov. 2020 06h30 HE
|
InspireMD
TEL AVIV, Israel, Nov. 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) (“Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke...
InspireMD to Report Third Quarter 2020 Financial Results on Monday, November 9, 2020 and Provide Corporate Update
02 nov. 2020 06h30 HE
|
InspireMD
TEL AVIV, Israel, Nov. 02, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) (“InspireMD” or the “Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the...
InspireMD Announces Renowned Interventional Cardiologist Gary S. Roubin, M.D., Ph.D., to Join Board of Directors
13 oct. 2020 06h30 HE
|
InspireMD
TEL AVIV, Israel, Oct. 13, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid...
InspireMD, Inc. Appoints Patrick Jamnik as Vice President of Business Development and Strategic Initiatives and Reports Inducement Grants Under NYSE American Company Guide §711(a)
06 oct. 2020 06h30 HE
|
InspireMD
TEL AVIV, Israel, Oct. 06, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) (“Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke...
InspireMD Announces Christina Brennan, M.D., MBA to Serve in Advisory Role for Pivotal Study of CGuard Carotid Stent System
10 sept. 2020 06h30 HE
|
InspireMD
TEL AVIV, Israel, Sept. 10, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by...
InspireMD Announces Approval of Investigational Device Exemption (IDE) for Pivotal Study of CGuard Carotid Stent System
08 sept. 2020 06h30 HE
|
InspireMD
TEL AVIV, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by...